A retrospective study of the epidemiology of vancomycin-resistant enterococci (VRE) in a regional hospital of central Italy in 2001-2018 demonstrated an increased VRE prevalence since 2016. A total of 113 VRE isolates, 89 E. faecium (VREfm) and 24 E. faecalis (VREfs), were collected in the study period. All strains showed high-level resistance to vancomycin; 107 also showed teicoplanin resistance. Altogether, 84 VREfm and 20 VREfs carried vanA, whereas 5 VREfm and 1 VREfs carried vanB. MLST analysis documented that 89 VREfm isolates mainly belonged to ST78, ST80, and ST117. Most strains were isolated from 2001 to 2007, ST78 being the predominant clone. VREfm re-emerged in 2016 with a prevalence of the ST80 lineage. Most VREfs were isolated from 2001 to 2006; although they belonged to 7 different STs, there was a prevalence of ST88 and ST6. Notably, ST88 was sporadically recovered throughout the study period. The increasing rate of VREfm isolation from 2016 to 2018 may be related to the influx of new successful clones and to the renewed and widespread use of vancomycin. Improved infection control measures in hospital wards should be adopted to limit the spread of new epidemic VRE strains.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688800 | PMC |
http://dx.doi.org/10.1007/s42770-020-00360-8 | DOI Listing |
J Glob Antimicrob Resist
January 2025
UCIBIO, Unidade de Ciências Biomoleculares Aplicadas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal; Laboratório Associado i4HB, Instituto para a Saúde e a Bioeconomia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal; UCIBIO, Unidade de Ciências Biomoleculares Aplicadas, Instituto Universitário de Ciências da Saúde (1H-TOXRUN, IUCS-CESPU), Gandra, Portugal. Electronic address:
Vancomycin-resistant Enterococcus faecium (VREfm) has become a critical opportunistic pathogen, urgently requiring new antimicrobial strategies due to its rising prevalence and significant impact on patient safety and healthcare costs. VREfm continues to evolve through mutations and the acquisition of new genes via horizontal gene transfer, contributing to resistance against several last-resort antibiotics. Although primarily hospital-associated, VREfm is also detected in the community, food chain, livestock, and environmental sources like wastewater, indicating diverse transmission pathways and the need for a One Health approach.
View Article and Find Full Text PDFMikrobiyol Bul
January 2025
Hacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Ankara.
Kanıtlar, klorheksidin glukonat (CHG) solüsyonuyla gerçekleştirilen banyonun, sağlık hizmeti ilişkili enfeksiyonlar (SHİE)'a neden olan mikroorganizmaların kolonizasyonunu azalttığını göstermektedir. Bu çalışmada yoğun bakım ünitesi (YBÜ)'nde yatan kanser hastalarında CHG banyosunun MRSA ve VRE kolonizasyonu üzerindeki etkilerinin değerlendirilmesi amaçlanmıştır. Bu çapraz tasarımlı çalışmada, kanser hastalarında standart su + sabun banyosuyla %2'lik CHG banyosu karşılaştırılmıştır.
View Article and Find Full Text PDFHeliyon
January 2025
Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Background: Oritavancin (ORT) is a new single-dose lipoglycopeptide showing activity against staphylococci and vancomycin-resistant enterococci. However, there is no data regarding its potential use as a catheter lock solution are scarce. We constructed an model to analyze the efficacy and stability of an ORT lock solution against the biofilm of staphylococci and enterococci over 7 days at 37 °C.
View Article and Find Full Text PDFBMC Res Notes
January 2025
Laboratory of Health and Life Science, Graduate School of Health and Sports Science, Juntendo University, Inzai, 270-1695, Japan.
Objective: Dictyostelium differentiation-inducing factors 1 and 3 [DIF-1 (1) and DIF-3 (2), respectively], along with their derivatives, such as Ph-DIF-1 (3) and Bu-DIF-3 (4), demonstrate antibacterial activity in vitro against Gram-positive bacteria, including methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-sensitive Enterococcus faecalis (VSE), and vancomycin-resistant Enterococcus faecium [VRE (VanA)]. This study investigates the therapeutic potential of DIF compounds against these Gram-positive bacteria.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Department of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, 73000, Thailand.
Background: The optimal pharmacokinetic and pharmacodynamic (PK/PD) parameters of vancomycin that can improve outcomes in enterococcal infections remain controversial. To clarify the therapeutic target for this antibiotic, this study aimed to determine vancomycin PK/PD parameters associated with efficacy in the early (during 72 h) or later (after 72 h) phase of treatment and nephrotoxicity in enterococcal bloodstream infection patients.
Methods: This multicenter retrospective study reviewed medical records of patients with enterococcal bloodstream infections treated with intravenous vancomycin infusion for at least 72 h between January 2016 and March 2024 at Phramongkutklao Hospital or Nopparatrajathanee Hospital in Bangkok, and Rachaburi Hospital in Rachaburi Province, Thailand.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!